MARKET

SNTI

SNTI

Senti Bioscience
NASDAQ
1.123
+0.043
+4.02%
Opening 12:22 01/09 EST
OPEN
1.120
PREV CLOSE
1.080
HIGH
1.160
LOW
1.100
VOLUME
181.86K
TURNOVER
--
52 WEEK HIGH
5.10
52 WEEK LOW
1.040
MARKET CAP
29.54M
P/E (TTM)
-0.4018
1D
5D
1M
3M
1Y
5Y
1D
Senti Biosciences CEO to Join Cell and Gene Therapy Panel at Biotech Showcase
Reuters · 3h ago
Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
Barchart · 9h ago
Weekly Report: what happened at SNTI last week (1229-0102)?
Weekly Report · 4d ago
Weekly Report: what happened at SNTI last week (1222-1226)?
Weekly Report · 12/29/2025 09:25
Weekly Report: what happened at SNTI last week (1215-1219)?
Weekly Report · 12/22/2025 09:25
Senti Biosciences Grants Stock Options to New Employee
Reuters · 12/18/2025 22:30
Senti Biosciences Announces New Employment Inducement Grants
Barchart · 12/18/2025 16:30
Promising Potential of SENTI-202 in Treating Acute Myeloid Leukemia: A Buy Recommendation Despite Financial Risks
TipRanks · 12/15/2025 14:16
More
About SNTI
Senti Biosciences, Inc. and its subsidiaries is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The Company is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.

Webull offers Senti Biosciences Inc stock information, including NASDAQ: SNTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNTI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNTI stock methods without spending real money on the virtual paper trading platform.